Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection (Q41660591)

6 October 2017

Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection (English)

1 reference

6 October 2017

1 reference

1 reference

Yao-Chun Hsu

1

1 reference

6 October 2017

Hsiu J Ho

2

1 reference

6 October 2017

Yen-Tsung Huang

3

1 reference

6 October 2017

Hsi-Hao Wang

4

1 reference

6 October 2017

Ming-Shiang Wu

5

1 reference

6 October 2017

Jaw-Town Lin

6

1 reference

6 October 2017

Chun-Ying Wu

7

1 reference

6 October 2017

language of work or name

English

0 references

publication date

14 November 2014

1 reference

6 October 2017

1 reference

6 October 2017

64

1 reference

6 October 2017

495-503

1 reference

6 October 2017

3

1 reference

Epidemiology of hepatitis B and C viruses: a global overview

6 October 2017

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Extrahepatic disease manifestations of HCV infection: some current issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Association of hepatitis C virus infection with risk of ESRD: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Hepatitis C virus infection and increased risk of cerebrovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Does hepatitis C virus infection increase risk for stroke? A population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Prevalence of hepatitis C serum antibody in autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Risk of stroke in long-term dialysis patients compared with the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Therapy of hepatitis C--back to the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

Kaplan–Meier methods yielded misleading results in competing risk scenarios

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308163

10.1136/GUTJNL-2014-308163

21 January 2018

Identifiers

DOI

1 reference

6 October 2017

1 reference